12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Capesaris: Phase II data

Data from 9 men with CRPC maintained on primary androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists alone in the open-label, U.S. Phase II G200707 trial showed that once-daily 2,000 mg oral Capesaris for 15 days did not significantly reduce serum total testosterone levels, but did significantly reduce free testosterone and PSA levels from...

Read the full 270 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >